As of 2024-12-14, the EV/EBITDA ratio of Creo Medical Group PLC (CREO.L) is -3.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CREO.L's latest enterprise value is 74.54 mil GBP. CREO.L's TTM EBITDA according to its financial statements is -21.60 mil GBP. Dividing these 2 quantities gives us the above CREO.L EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 13.4x | 10.4x |
| Forward P/E multiples | 12.5x - 15.0x | 13.7x |
| Fair Price | (40.14) - 283.02 | 101.47 |
| Upside | -337.9% - 1577.1% | 501.3% |
| Date | EV/EBITDA |
| 2024-12-09 | -2.99 |
| 2024-12-06 | -3.04 |
| 2024-12-05 | -3.07 |
| 2024-12-04 | -3.14 |
| 2024-12-03 | -3.21 |
| 2024-12-02 | -3.28 |
| 2024-11-29 | -3.28 |
| 2024-11-28 | -3.28 |
| 2024-11-27 | -3.28 |
| 2024-11-26 | -3.28 |
| 2024-11-25 | -3.31 |
| 2024-11-22 | -3.40 |
| 2024-11-21 | -3.31 |
| 2024-11-20 | -3.33 |
| 2024-11-19 | -3.43 |
| 2024-11-18 | -3.43 |
| 2024-11-15 | -3.52 |
| 2024-11-14 | -3.45 |
| 2024-11-13 | -3.57 |
| 2024-11-12 | -3.72 |
| 2024-11-11 | -3.78 |
| 2024-11-08 | -3.67 |
| 2024-11-07 | -3.62 |
| 2024-11-06 | -3.72 |
| 2024-11-05 | -3.81 |
| 2024-11-04 | -3.81 |
| 2024-11-01 | -3.96 |
| 2024-10-31 | -3.98 |
| 2024-10-30 | -4.05 |
| 2024-10-29 | -4.00 |
| 2024-10-28 | -4.05 |
| 2024-10-25 | -4.05 |
| 2024-10-24 | -4.05 |
| 2024-10-23 | -4.10 |
| 2024-10-22 | -4.10 |
| 2024-10-21 | -4.10 |
| 2024-10-18 | -4.10 |
| 2024-10-17 | -4.22 |
| 2024-10-16 | -4.20 |
| 2024-10-15 | -4.29 |
| 2024-10-14 | -4.50 |
| 2024-10-11 | -4.49 |
| 2024-10-10 | -4.49 |
| 2024-10-09 | -4.49 |
| 2024-10-08 | -4.50 |
| 2024-10-07 | -4.38 |
| 2024-10-04 | -4.39 |
| 2024-10-03 | -4.52 |
| 2024-10-02 | -4.26 |
| 2024-10-01 | -4.40 |